Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$600,000.00
May 1, 2026
For-profit organization
CIIP Singapore - PEGASUS-BPE-CAR-T: Cost-Effective CAR-TCR Development with Pegasus Bio's BPE Plasmid Platform
1043376
CIIP Singapore -PEGASUS-BPE-CAR-T: Cell and gene therapy manufacturing faces major bottlenecks due to low-yield, high-cost, and difficult-to-scale plasmid DNA systems that limit efficient viral production. Pegasus Bio and CellVec are partnering to commercialize a high-performance plasmid DNA vector platform optimized for CAR-T and CAR-NK manufacturing. The project delivers a cost-effective, scalable, and regulatory-ready solution for gene delivery, improving expression, safety, and production efficiency. The PB BPE plasmid system will be offered to CGT developers through licensing and CDMO partnerships, with GMP processes transferred to qualified manufacturers. Joint IP will be protected through global patents, and a targeted market campaign will support commercialization.
$3,975.00
Mar 11, 2026
For-profit organization
Participation in the Canadian Co-Innovation Mission To The Eureka GIS and Swiss Biotech Day in Switzerland – May 2026
1040912
Participation in the Canadian medical biotechnology co-innovation mission to the Eureka Global Innovation Summit and Swiss Biotech Day in Switzerland – May 3 to 8, 2026. Delegation led by the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to develop international partnerships and potential project ideas under the Eureka Programs.
$514,123.00
Apr 1, 2025
For-profit organization
UK Biomanufacturing - 10141267 - BPE Human Vaccines - Implementation of High Yielding Plasmid DNA Platform for Human Vaccine Manufacturing
1028954
This project leverages the combined vaccine development platform technologies of Pegasus Biotech, ConserV Bio and 4BaseBio to evaluate and enhance the manufacturing capability of a novel Canadian plasmid DNA technology platform (BPE) in the production of a new class of human influenza vaccines based on ConserV Bio's FLU-v technology.
$50,000.00
Nov 13, 2024
For-profit organization
226832
226832
Hire expertise in international business development
$349,715.00
Apr 1, 2024
For-profit organization
BPE Plasmid Scale Up
1016236
The BPE technology is a novel, DNA plasmid backbone/production method that is ultra-low-cost, and has superior transfection efficiency. The technology has been demonstrated at lab scale (1.0 L fermentation), and needs to be scaled up to a commercially viable pilot scale to aid commercialization, and support projects to market the technology. This project ultimately scales up the process to 20-30 L fermentation along with associated downstream processes.
$3,222.00
Feb 29, 2024
For-profit organization
CIIP PDA – Pegasus Biotech Incorporated – 2023-24
7457826 P014190001
The purpose of the Canadian International Innovation Program (CIIP) contribution agreement is to support Canadian SMEs identify international partners in CIIP target countries for industrial research and development collaboration that has good potential for commercialization.
$50,000.00
Feb 1, 2024
For-profit organization
ICAP – International Co-Innovation Action Plan
1014691
This International Co-Innovation Action Program (ICAP) project will prepare the Firm to enter into future international co-innovation work.
$298,514.00
Jan 2, 2023
For-profit organization
BPE Technology Development
999756
Pegasus Biotech is developing the process and analytical methods to commercialize the BPE plasmid technology as a DNA plasmid production platform.
$12,004.00
Nov 14, 2022
For-profit organization
IP Assist: Intellectual Property Strategy Engagement
997947
The Project will support development of intellectual property capacity within the Firm.
$49,992.00
Apr 1, 2022
For-profit organization
DNA Vaccine Platform Development
988568
Pegasus Biotech is developing a DNA vaccine development platform to provide accelerated vaccine development services to new and existing clients.